NASDAQ:TNGX

Tango Therapeutics (TNGX) Stock Forecast, Price & News

$7.81

+3.98 (+103.92%)

(As of 08/9/2023 ET)

Compare

Today's Range: $5.00
▼
$9.39
50-Day Range: $2.67
▼
$7.81
52-Week Range: $2.47
▼
$9.39

Volume: 74.84 million shs
Average Volume: 694,361 shs
Market Capitalization: $690.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Tango Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 104.9% Upside
$16.00 Price Target
Short Interest: Healthy
3.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.38
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.40) to ($1.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

382nd out of 970 stocks

Pharmaceutical Preparations Industry

175th out of 458 stocks

3.5

Analyst's Opinion

Consensus Rating
Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, Tango Therapeutics has a forecasted upside of 104.9% from its current price of $7.81.
Amount of Analyst Coverage
Tango Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.45% of the float of Tango Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tango Therapeutics has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Tango Therapeutics has recently decreased by 1.32%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Tango Therapeutics does not currently pay a dividend.
Dividend Growth
Tango Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TNGX.

2.4

News and Social Media Coverage

News Sentiment
Tango Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Tango Therapeutics this week, compared to 1 article on an average week.
Search Interest
3 people have searched for TNGX on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tango Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Tango Therapeutics is held by insiders.
Percentage Held by Institutions
78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Tango Therapeutics are expected to grow in the coming year, from ($1.40) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tango Therapeutics is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tango Therapeutics is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tango Therapeutics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

TNGX Price History

30 days | 90 days | 365 days | Advanced Chart

TNGX Stock News Headlines

August 9, 2023 | investorplace.com

Why Is Tango Therapeutics (TNGX) Stock Up 117% Today?

August 9, 2023 | americanbankingnews.com

Tango Therapeutics (NASDAQ:TNGX) Announces Quarterly Earnings Results

August 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 8, 2023 | msn.com

HC Wainwright & Co. Reiterates Tango Therapeutics (TNGX) Buy Recommendation

August 8, 2023 | markets.businessinsider.com

Barclays Releases a Buy Rating on Tango Therapeutics (TNGX)

August 8, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

August 7, 2023 | finanznachrichten.de

Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

August 7, 2023 | msn.com

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates

August 10, 2023 | Chaikin Analytics (Ad)

Forget NVDA. Buy this A.I. stock instead

Dozens of 100% - 1,000% opportunities over the last decade have led to this one under-the-radar A.I. stock... MORE HERE...

August 7, 2023 | finance.yahoo.com

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

July 26, 2023 | seekingalpha.com

Tango Therapeutics: Partial Phase 1 Data Has Not Helped

July 24, 2023 | finance.yahoo.com

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

July 10, 2023 | finance.yahoo.com

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

June 26, 2023 | markets.businessinsider.com

Tango Therapeutics (TNGX) Gets a Buy from Barclays

June 1, 2023 | finance.yahoo.com

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 12, 2023 | msn.com

Wedbush Reiterates Tango Therapeutics (TNGX) Outperform Recommendation

May 9, 2023 | finance.yahoo.com

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2023 | msn.com

Tango Therapeutics: Q1 Earnings Insights

May 9, 2023 | markets.businessinsider.com

Goldman Sachs Sticks to Its Buy Rating for Tango Therapeutics (TNGX)

May 9, 2023 | finanznachrichten.de

Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 9, 2023 | finance.yahoo.com

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

April 18, 2023 | finance.yahoo.com

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

April 3, 2023 | tmcnet.com

Tango Therapeutics Announces FDA Clearance of Investigational New

April 3, 2023 | finance.yahoo.com

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

March 28, 2023 | msn.com

Tango Therapeutics GAAP EPS of -$0.33 beats by $0.03, revenue of $6.41M beats by $0.09M

March 28, 2023 | msn.com

Looking Into Tango Therapeutics's Return On Capital Employed

March 28, 2023 | markets.businessinsider.com

Tango Therapeutics (TNGX) Receives a Buy from H.C. Wainwright

See More Headlines

Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Company Calendar

Last Earnings: 8/07/2023
Today: 8/09/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TNGX
CUSIP: N/A
CIK: 1819133
Web: www.tangotx.com
Phone: 857-320-4900
Fax: N/A
Employees: 110
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.00
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +104.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,180,000.00
Net Margins: -317.04%
Pretax Margin: -446.04%
Return on Equity: -42.74%
Return on Assets: -24.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.39
Quick Ratio: 6.39

Sales & Book Value

Annual Sales: $24.86 million
Price / Sales: 27.77
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.83 per share
Price / Book: 2.76

Miscellaneous

Outstanding Shares: 88,410,000
Free Float: 82,926,000
Market Cap: $690.48 million
Optionable: Not Optionable
Beta: 1.73

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Barbara L. Weber M.D. (Age 66)
Pres, CEO & Director
Comp: $941.16k

Ms. Daniella Beckman CPA (Age 44)
Chief Financial Officer
Comp: $619.13k

Dr. Alan Huang Ph.D. (Age 50)
Chief Scientific Officer
Comp: $621.9k

Dr. Alan Ashworth FRS (Age 62)
Ph.D., Founder & Member of Scientific Advisory Board

Dr. Levi Garraway M.D. (Age 54)
Ph.D., Founder

Dr. William G. Kaelin Jr. (Age 65)
M.D., Founder & Member of Scientific Advisory Board

Dr. Timothy K. Lu M.D. (Age 42)
Ph.D., Founder

Dr. Antoni Ribas M.D. (Age 56)
Ph.D., Founder & Member of Scientific Advisory Board

Mr. Douglas J. Barry Esq. (Age 53)
J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Mr. John C. Ross M.S.
VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TNGX Stock - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings or view top-rated stocks.
What is Tango Therapeutics' stock price forecast for 2023?: 1 Wall Street research analysts have issued 12-month price objectives for Tango Therapeutics' shares. Their TNGX share price forecasts range from $11.00 to $21.00. On average, they anticipate the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 104.9% from the stock's current price.
View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts.
How have TNGX shares performed in 2023?: Tango Therapeutics' stock was trading at $7.25 on January 1st, 2023. Since then, TNGX shares have increased by 7.7% and is now trading at $7.81.
View the best growth stocks for 2023 here.
When is Tango Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our TNGX earnings forecast.
How were Tango Therapeutics' earnings last quarter?: Tango Therapeutics, Inc. (NASDAQ:TNGX) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.10. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $7 million. Tango Therapeutics had a negative net margin of 317.04% and a negative trailing twelve-month return on equity of 42.74%.
What ETF holds Tango Therapeutics' stock ?: Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio.

What is Tango Therapeutics' stock symbol?: Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX."
Who are Tango Therapeutics' major shareholders?: Tango Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Swiss National Bank (0.13%), Barclays PLC (0.06%), Exchange Traded Concepts LLC (0.04%), Clear Harbor Asset Management LLC (0.02%), Allspring Global Investments Holdings LLC (0.02%) and Allspring Global Investments Holdings LLC (0.02%).
View institutional ownership trends.
How do I buy shares of Tango Therapeutics?: Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tango Therapeutics' stock price today?: One share of TNGX stock can currently be purchased for approximately $7.81.
How much money does Tango Therapeutics make?: Tango Therapeutics (NASDAQ:TNGX) has a market capitalization of $690.48 million and generates $24.86 million in revenue each year. The company earns $-108,180,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.
How many employees does Tango Therapeutics have?: The company employs 110 workers across the globe.
How can I contact Tango Therapeutics?: Tango Therapeutics' mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.tangotx.com. The company can be reached via phone at 857-320-4900.

This page (NASDAQ:TNGX) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial